AIM Vaccine (HKG:6660) is looking to raise net proceeds of HK$74.7 million from the placement of 15.5 million shares to Factorial Master Fund at HK$5.01 apiece, a Friday filing with the Hong Kong bourse said.
The shares represent 3.05% and 1.26% of its enlarged H share and issued share capital.
The drugmaker will use proceeds from the issue to accelerate the R&D of various pre-clinical and clinical programs; develop, market, and commercialize new products; and for working capital.
Shares of the company were down nearly 12% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。